The Clatterbridge Cancer Centre NHS Foundation Trust

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, skin disorder, skin neoplasm, uveal disorder, uveal melanoma	Active, not recruiting	Phase 2 / Phase 3	2026-02-17	NCT05987332
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 3	2025-10-14	NCT02767804
Tumour Characterisation to Guide Experimental Targeted Therapy - National	cancer, neoplasm	Recruiting	Not stated	2024-02-07	NCT04723316

Clinical trials